Comment: This highly recommended pharma practice has one of the broadest setups in the market. Thanks to its successful mix of regulatory expertise, many years of experience in major international projects, transactions and licensing deals, as well as its proven industry specialties in public procurement and antitrust, the firm is hot on the heels of the market leaders. This is further aided by Baker’s phenomenal setup at interfaces such as compliance and IT law, where the industry’s need for advice remains high due to topics such as anticorruption and e-health. Esp. in terms of regulatory advice, the practice maintains long-standing, stable client relationships with a large number of reputable pharma and medical product companies. The firm also profits from its strong international network with regard to advice on cross-border projects, in which Baker, just like similarly structured practices from major firms (e.g. Clifford Chance, Freshfields and Hogan Lovells), has long since specialized. The German pharma practice, for example, is managing regulatory integration following a large transaction on behalf of a globally active client. Moreover, the team was involved in the sale of Ganymed in one of the most important biotech deals of the past year. The public procurement practice was also able to chalk up a wonderful success for client Novartis in the prominent series of proceedings concerning Imatinib.
Strengths: Regulatory advice, esp. in major international projects. ?M&A transactions and expertise in biotech. Industry-specific ?public procurement and ?antitrust.
Recommended: Dr. Thilo Räpple (regulatory aspects), Dr. Constanze Ulmer-Eilfort (licenses), Dr. Marc Gabriel (public procurement), Dr. Christian Burholt (“gives practical advice and is extremely quick”, client; antitrust).
Practice: All-round advice to the industry in strategic projects, esp. regulatory issues, pharma advertising, unfair competition disputes, medical product law and research contracts. Also transaction advice, ?compliance, ?product liability. Advice on the interface between social and procurement law. In Munich: advice on licenses and IP with a pharma/biotech angle. Also ?patents and ?antitrust besides ?IT (data protection). Clients: researchers/manufacturers of pharmaceuticals and medical products, biotech companies. (Core team: 6 partners, 8 associates)
Clients: ?? Ganymed shareholders on IP in sale to Astellas; Novartis Pharma on public procurement, incl. in open-house process concerning Imatinib/cancer drug Glivec; Grünenthal on acquisition of Adhesys Medical from GSK; international pharma entrepreneur on introduction of a global health cloud platform; medical device company in proceedings against the Federal Institute for Drugs and Medical Devices.
  • Teilen